Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 5

Results For "Indian-Council-of-Medical-Research"

60 News Found

ICMR approves Krivida Novus RT-PCR kit
Medical Device | January 19, 2022

ICMR approves Krivida Novus RT-PCR kit

Krivida Novus can detect the Omicron variant and its sub-lineages in 45 minutes


Odisha is the first state to place order for OmiSure to detect Omicron
Medical Device | January 10, 2022

Odisha is the first state to place order for OmiSure to detect Omicron

TATA MD’s OmiSure is the only test approved by the ICMR for RT-PCR detection of the Omicron variant


Tata Medical develops OmiSure to detect Omicron
Medical Device | January 05, 2022

Tata Medical develops OmiSure to detect Omicron

The test kit is compatible with all standard Real-Time PCR machines with a test run time of 85 minutes. The result turnaround time, including sample collection and RNA extraction, is 130 minutes


ICMR invites EOI for Omicron detection kits
News | December 20, 2021

ICMR invites EOI for Omicron detection kits

The Indian Council of Medical Research (ICMR), intends to enter into non-exclusive agreements with companies


ICMR Dibrugarh designs kit to detect Omicron variant in two hours
News | December 13, 2021

ICMR Dibrugarh designs kit to detect Omicron variant in two hours

GCC Biotech is manufacturing the kits on a public-private partnership (PPP) model


Over one lakh SARS-CoV-2 genomes sequenced till November
Policy | December 03, 2021

Over one lakh SARS-CoV-2 genomes sequenced till November

Union Minister Dr Jitendra Singh said a large number of Covid-19 bio-repositories and samples were made available to academia and industry


ICMR approves Meril’s Rapid Antigen Test kit
Drug Approval | November 25, 2021

ICMR approves Meril’s Rapid Antigen Test kit

The company is marketing the kit under the brand name CoviFind and it can detect the infection in 15 minutes


Covaxin well tolerated with no safety concerns: Lancet
News | November 12, 2021

Covaxin well tolerated with no safety concerns: Lancet

Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the Delta variant at 65.2%


Takeda receives the Arogaya CIBioD Leadership Award
Public Health | November 10, 2021

Takeda receives the Arogaya CIBioD Leadership Award

It was recognized for its holistic initiatives designed to improve the quality of life and standards of care for patients


AstraZeneca partners with India-Sweden Healthcare Innovation Centre and AIIMS to upskill nurses
Public Health | October 28, 2021

AstraZeneca partners with India-Sweden Healthcare Innovation Centre and AIIMS to upskill nurses

This capability programme aims to upskill 5000 nurses across the country in the next year by converting the current modules into an e-learning one